New drug targets common kidney disease
Lab results show that a new drug is effective in treating a very common kidney disease—although it’s a few years away from clinical testing.
Christpher Leaman, head of biotech firm Endocyte, Inc., was particularly interested in the rapamycin research because he himself has polycystic kidney disease (PKD).
He contacted Thomas Weimb at the University of California, Santa Barbara to develop a research partnership on a new drug for PKD—based on Weimbs’ earlier research.
Full story at Futurity.
Photo credit: UCSB
0 Comments